On May 5, 2022 CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, reported that it has received a Grant of Patent notice by the Patent Registry, Intellectual Property Department, The Government of the Hong Kong Special Administrative Region (Press release, CNBX Pharmaceuticals, MAY 5, 2022, View Source [SID1234613839]). Said notice relates to the Company’s patent titled: System and Method for High Throughput Screening of Cancer Cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company further reported that it believes that the granting of this patent by the Hong Kong Patent Registry validates its innovative approach to drug discovery in using data obtained from high throughput screening (HTS) of compounds on various types of cancer cells to elucidate and identify specific compounds that are most effective as anti-cancer agents.

This process has already been instrumental for the Company in producing several promising cancer treatment drug candidates, which are now at various stages of the regulatory pathway, including its novel drug candidate RCC-33 for the treatment of colorectal cancer.